Background Common fetal aneuploidies include Down syndrome (trisomy 21 or T21),
Edward syndrome (trisomy 18 or T18), Patau syndrome (trisomy 13 or T13), Turner …

Objective In this study, we expanded conventional cell‐free fetal DNA (cfDNA)‐based non‐
invasive prenatal testing (NIPT) to cover the entire genome. We aimed to compare the …

Non-invasive prenatal testing (NIPT) through the analysis of cell free (cf) DNA is
revolutionizing prenatal screening for fetal aneuploidy. Current methods used in clinical …

Noninvasive prenatal testing (NIPT) using cell‐free DNA (cfDNA) from maternal serum has
been clinically available since 2011. This technology has revolutionized our ability to screen …

Non-invasive prenatal testing (NIPT) is performed worldwide to detect common
chromosomal aneuploidies. The analysis of cell-free DNA (cfDNA) in maternal blood for …

Background This paper describes the clinical practice and performance of cell-free DNA
sequencing-based non-invasive prenatal testing (NIPT) as a screening method for fetal …

The goal to noninvasively detect fetal aneuploidies using circulating cell‐free fetal DNA in
the maternal plasma seems to be achieved by the use of massively parallel sequencing …

Fetal aneuploidies are among the most common causes of miscarriages, perinatal mortality
and neurodevelopmental impairment. During the last 70 years, many efforts have been …

Background In high-risk pregnant women, noninvasive prenatal testing with the use of
massively parallel sequencing of maternal plasma cell-free DNA (cfDNA testing) accurately …

Non invasive prenatal Testing (NIPT) is changing the practice of prenatal diagnosis
worldwide. It provides high sensitivity and specificity in screening for common aneuploidies …